4. Anafilaksis_Deasy F

7/24/2019 4. Anafilaksis_Deasy F

1/40

!"#$%$&$'($#$$# )#$*+&$'(+(

,"$(- /"%$0$-$#+

,"1$0%"2"#345/ 6&27 !"#-$'+% ,$&$2

/$'7&%$( 8"9:'%"0$# ;#+


2/40

A:1+'

! !"#$%&'('%#

! !%)*+,-,*(*.,

! /%01%2%# 3(,#,-! 4,%.#*-,- $%# 4,%.#*-,- 6%#$,#.

! !"0"2,7-%%# (%1*2%)*2,'0

! 8%)%(%7-%#%! !2*.#*-,-

! !"#9".%&%#

! 3"-,0:'(%#


3/40

!"#9$B7&7$#


4/40

,"*+#+(+ $#$*+&$'(+(

! ;#%+,(%7-,- %$%(%& 2"%7-, &,:"2-"#-,),+,)%-

-,-)"0,7 1"2%) $%# 0"#.%#9%0 -),(%& ?2"%7-, %#%+,(%7)*,$@ -'$%& 0'(%,$,),#..%(7%# A $,.%#), $"#.%# ,-),(%&?:-"'$*%("2.,@

! B"%7-, ,#, $%:%) )"2


5/40

8&$(+*+'$(+ $#$*+&$'(+( ("(7$+ %"02+#:&:=+ @$07

+,-.(//,( 1234 &) .56 7&8*/&% (,9&(:5.);


6/40

6#(+9"#(+ C 10" !99;(,5EFKKJEE@LKG$Q

R&).(%&< O4 &) .56 H5*( #S' C55&


7/40

/$'%:0D*$'%:0 -$#= 2"21"#=$07B+ +#(+9"# 9$#

'"1$0$B$# $#$*+&$'(+(

/$'%:0 E*"'

;(+$ T"1,& -"2,#. :%$% $"=%-% $%2,:%$% %#%7P%#%7N !%$% '-,% (%##-,$"#-, %#%+,(%7-,- 0"#,#.7%) :%$% (*7%-, $"#.%# :%:%2%# -,#%2 0%)%&%2,

F%#. 2"#$%&I 0,-%(#F% :%$% 1"(%&%# 1'0, 1%.,%# ')%2%N

!"#-$'+%1"#-"0%$ ;-0%I :"#F%7,) :%2' *1-)2'7),+ 72*#,7I :"#F%7,) 7%2$,*E%-7'("2I 0%-)*-,)*-,-I

$%# :"#F%7,) -"( 0%-) 7(*#%( 1"2&'1'#.%# $"#.%# :"#,#.7%)%# 2,-,7*

%#%+,(%7-,- F%#. 1"2%) $%# +%)%(N


8/40

H$B$#D@$B$# -$#= ("0+#= 9+&$1:0'$# 2"#-"@$@'$# $#$*+&$'(+(

8$%"=:0+ I:#%:B

)#%+@+:%+'$ !"#,-,(,# $%# %#%(*.#F%I %#),1,*),7% VP(%7)%0I -"+%(*-:*2,#I )")2%9F9(,#"I"2F)&2*0F9,#N

J@$% )#%+ 6#*&$2$(+ K:# 4%"0:+9LJ)6K4M

U%(,9F(%)"I ,1':2*+"#I ,#$*0")&%9,#

)#$&="(+'#$0':%+' W*2+,#I7*$",#I 0":2*1%0%)

)#$(%"%+'&:'$& !2*9%,#"I (,$*9%,#"I 9*9%,#"

)#$(%"%+' 7272 8&,*:"#)%(

J@$% 1"&"2$( :%:% U'X%0")&*#,'0I )'1*9'2%2,#"I :%#9'2*#,'0

!0:97' 9$0$B 9$# $#%+("0$ 82%#-+'-, "2,)2*-,)I ("'7*-,)I )2*01*-,)Y ,0'#*.(*1'(,#Y %#),)*7-,# $,+)"2,I )")%#'-I2%1,"-Y%#),1,-% '(%2 $%# (%1%P(%1%

H$B$# 9+$=#:(%+' W"$,% 2%$,*7*#)2%- ,*#,7I+('*2"-9",#

5$'$#$# 3%9%#.P7%9%#.%#I7"2%#.I ,7%#I-'-'I )"('2

H+($ ("#=$%$# ("0$#==$ 8%=*#I :"#F"#.%) C=%-:-DI ("1%&0%$'I-"0') %:,I7%(%


9/40

!$%:*+(+:&:=+


10/40

8&$(+*+'$(+ 1$%:*+(+:&:=+ $#$*+&$'(+(

5"'$#+(2" I:#%:B

627#:&:=+(O!"#$%&'&(%&() 5$'$#$#J@$%D:@$%$#

P+=+%$# 9$#("#=$%$# ("0$#==$)'%+


11/40

5"'$#+(2" 0"$'(+ B+1"0("#(+%+*+%$( %+1" 6

L,11&%,.)& 34'&05&(5,),6,)4M

"#$%&'$%()

(* ,-. #/001 ')2

1$%340'$%() (*

567 #0'11 18%$#9%)6%) : #/001

;%(14/'$/2 /=>(14%2 3/2%'$((14


12/40

Biogenic amines(e.g., histamines)

Lipid mediators(e.g., PAF, PGD2, LTC4)

Vascular leak

Broncho-constriction

Broncho-constriction

Intestinalhypermotility

Inflammation

Tissue

damage

Enzymes

(e.g., tryptase)

Cytokines(e.g., TNF)

Lipid mediators(e.g., PAF, PGD2, LTC4)

Activatedmast cell

(or basophil)

E*"' @+:&:=+( 2"9+$%:0 0"$'(+ B+1"0("#(+%+*+%$( %+1" 6

C??./ CV4 W*:-)9.( CX4 P*55.* 16 H&55;5.< .(% O,5&:;5.< !99;(,5,">4 L)- &%4 EFKT


13/40

5"9+$%:0 -$#= 9+&"1$('$# :&"B ("& 2$(% 9$# @$(:*+& 1$9$

$#$*+&$'(+(

5"9+$%:0 E*"'

5"%$@:&+% )($2 )0$'+9:#$%

H>/)&*(>55&;Y,)


14/40

P$2@$0$# 8&+#+(


15/40

5$#+*"(%$(+ $#$*+&$'(+( LSM

! 6"2E%2,%-,$%(%0 &%( %=%( 0'(% ),01'(#F% ."


16/40

5$#+*"(%$(+ $#$*+&$'(+( LVM

! ;#%+,(%7-,- +%-" (%01%) C2"%7-, 1,+%-,7D GLW'#9'(#F% 7"01%(, ."


17/40

5$#+*"(%$(+ $#$*+&$'(+( LWM

! ;#%+,(%7-,- ?'


18/40

P"X$&$ 9$# %$#9$ $#$*+&$'(+(

47(7#$# ($0$* 17($%

!'-,#.I $,-*2,"#)%-,I :,#.-%#I 7"


19/40


20/40

,+$=#:(+( 9$# ,+$=#:(+( H$#9+#=


21/40

)#$*+&$'(+( ($#=$% 27#='+# @+&$ ($&$B ($%79$0+ %+=$ '0+%"0+$ @"0+'7% %"01"#7B+ [

LN 3*#$,-, -%7,) $"#.%# *#-") %7') C1"1"2%:% 0"#,) -%0:%, $"#.%# 1"1"2%:%


22/40

,+$=#:(+( @$#9+#=

! B"%7-, E%-*E%.%(

! >#+%27 0,*7%2$

! _,:*.(,7"0,%

! R01*(, :%2'

! ;#.,*"$"0% &"2"$,)"2

! U,#$2*0% W'#9&%'-"#

! B"%7-, &,-)"2,-

! U,#$2*0% 7%2-,#*,$


23/40

!"2"0+'($$# G$@:0$%:0+72


24/40

8$9$0 %0+1%$(" ("072

! 0"#,#.7%) :%$% :"#$"2,)% %#%+,(%7-,- $%#

0%-)*-,)*-,- -,-)"0,7

! 3%$%2 :'#9%7 $,9%:%, :%$% JM P cM 0"#,)-")"(%& ."


25/40

8$9$0 B+(%$2+#

! 3%$%2 &,-)%0,# $%(%0 :(%-0%! $%(%0 O P LM

0"#,) -")"(%& ."


26/40

A$%$&$'($#$


27/40

A$%$&$'($#$ 9$($0

! U"),%: ,#-),)'-, :"(%F%#%# 7"-"&%)%#-"(%F%7#F% 0"0:'#F%, :2*)*7*( )"2)'(,-

)"#)%#. 7".%=%)$%2'2%)%# C:"#."#%(%#I

$,%.#*-,- A )%)%(%7-%#% %#%+,(%7-,-D! W"(%7'7%# (%),&%# :2*)*7*( )"2-"1') -"9%2%

)"2%)'2

! U"0'% )"#%.% 0"$,- -"(%(' $%(%0 7"%$%%#-,%: -"$,% '#)'7 0"#.&%$%:, A 0"#%#.%#,

7%-'- %#%+,(%7-,- -"-'%, :2*)*7*(


28/40

G$#='$BD&$#='$B %$%$&$'($#$ 9$($0 LSM

LN U"1,-% 0'#.7,# &"#),7%# :%:%2%# )"2&%$%:

:"#9")'-I0,-%(#F% &"#),7%# *1%) ,#)2%E"#% F%#.

0'#.7,# 0"#9")'-7%# ."


29/40

G$#='$BD&$#='$B %$%$&$'($#$ 9$($0 LVM

! U"9%2% 9":%) $%# -,0'()%#I (%7'7%# (%#.7%& SI KI A ON

SN W,#)%(%& :"2)*(*#.%#),0 2"-'-,)%-, 2'0%& -%7,)

%)%' :'-%) 7"-"&%)%# 0%-F%2%7%) )"2$"7%)

KN >#W :%$%

0,$P%#)"2*(%)"2%( :%&% C*)*) R./);/ 5.)&


30/40

G$#='$BD&$#='$B %$%$&$'($#$ 9$($0 LWM

JN 6"2,7%# *7-,."# $"#.%# %(,2%# JP\ T:0 $"#.%#0%-7"2 %)%' 0"(%(',


31/40

A"0$1+ &+#+ '"97$

! ;#),&,-)%0,# _L C0,-%(#F% :-5,5'


32/40

!0:=#:(+(


33/40

!0:=#:(+(

! U%#.%) )"2.%#)'#. :%$% :"#."#%(%# $,#,

."


34/40

!"#Q"=$B$#


35/40

!"#Q"=$B$# $#$*+&$'(+( @"07&$#= 9+ '"279+$# B$0+

U,0*#- `RBI ") %(N k*2($ ;(("2.F b2.%#,[%),*# .',$"(,#"- +*2 )&" %--"--0"#) %#$ 0%#%."0"#) *+ %#%:&F(%X,- HMLLN BC3 +,;


36/40

4"@"&72 2"2@"0+'$# :@$%D:@$%$# LSM

! 4*7)"2 &%2'- 0"#9%)%) -"9%2% )"(,), %$%#F% 2,=%F%)%)*:,I 2,=%F%) %("2., *1%) -"1"('0#F%I


37/40

4"@"&72 2"2@"0+'$# :@$%D:@$%$# LVM

! _,#$%2, :"0%7%,%# *1%) -"9%2% ,#)"20,)"#N 6"2,)%&':"#$"2,)% )"#)%#. 7"0'#.7,#%# 2"%7-, F%#. )"2


38/40

8"(+217&$#


39/40

! ;#%+,(%7-,- %$%(%& 2"%7-, &,:"2-"#-,),+,)%- -,-)"0,7 1"2%)$%# 0"#.%#9%0


40/40

4. Anafilaksis_Deasy F

Documents

Transcript of 4. Anafilaksis_Deasy F